Bristol Myers Squibb has multiple FDA-approved CAR T cell therapies that utilize one centralized platform and one dedicated team with CAR T cell therapy expertise.
ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
The ABECMA treatment journey is multistep and involves collaboration between a primary oncologist and a certified ABECMA treatment center. Here, you can see an overview of the process. Your role is highlighted within the relevant steps below.
Defined as being in market since 2021 as the first CAR T cell therapy in RRMM.
Primary Oncologist
Certified CAR T Cell Therapy Treatment Center
Triple-class exposed (patients who have received an IMiD® agent, a PI, and an anti-CD38 monoclonal antibody) and who have received at least 4 prior lines of therapy
Clinically fit (eg, good performance status and adequate organ function)
Once a patient is referred to a certified treatment center, the treatment center will evaluate patient eligibility and begin initial stages of the treatment process if appropriate.
Find a certified treatment center at AbecmaFinder.com
The ABECMA treatment process1
Expand All
>98%
Manufacturing
success rate in the pivotal study†
28 DAYS
Target turnaround time for commercial manufacturing (for >90% of batches)2‡
Bristol Myers Squibb has multiple FDA-approved CAR T cell therapies that utilize one centralized platform and one dedicated team with CAR T cell therapy expertise.
The manufacturing success rate is defined as the ability to manufacture the product. The risk of manufacturing failure was 1.5% (2/135) in the pivotal study.
Manfacturing turnaround times may vary. In the pivotal study, the median time from leukapheresis to product availability was 33 days (range: 26 to 49 days) in the KarMMa study.
CAR=chimeric antigen receptor; CBC=complete blood count; CRS=cytokine release syndrome; IV=intravenous; NT=neurologic toxicity; PI=proteasome inhibitor; REMS=Risk Evaluation and Mitigation Strategy; RRMM=relapsed/refractory multiple myeloma.